Hogan Lovells advises Novartis on Vedere Bio acquisition
New York, 10 November 2020 – International law firm Hogan Lovells is advising Novartis on its acquisition of Vedere Bio, a transaction which will add a powerful new platform for AAV-based delivery of gene therapies and a best-in-class optogenetics program to help reimagine the treatment and prevention of vision loss and blindness.
It further builds on the company’s commitment in cell and gene therapy, and will enable Novartis to further advance its efforts to bring transformative therapies to a wide range of patients with blinding diseases.
Novartis is broadening its footprint in the gene therapy space, with a focus on three distinct platforms—AAVs, chimeric antigen receptor T-cells (CAR-Ts) and clustered regularly interspaced short palindromic repeats (CRISPR). The acquisition of Vedere Bio’s unique technology is the latest addition to the company’s expanding therapeutic arsenal.
The Hogan Lovells team was led by M&A partner and Head of the Corporate & Finance practice group in New York, Adam Golden, and Private Equity & Funds partner Michael Szlamkowicz. M&A senior associates Jeffrey Jay and Brittany Raway also assisted in the deal. Other key support included Tax, Pensions & Benefits partners Carin Carithers, Christine Lane, and Kurt Lawson; Global Regulatory partners William Ferreira and Susan Lee; counsel Mike Applebaum, and Tao Y Leung; senior associates Lauren Battaglia, Steven Palyca, David Mitchell, David Steenburg; and associates Andrew Brandes, Kate McGuigan, and Sarah Godwin.
The full news release can be accessed here.